{"id":18772,"date":"2022-09-06T17:38:27","date_gmt":"2022-09-06T12:08:27","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18772"},"modified":"2022-09-06T20:38:48","modified_gmt":"2022-09-06T15:08:48","slug":"pharma-news-for-azurity-sobi-sanofi-amgen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen","title":{"rendered":"AstraZeneca\u2019s Imfinzi for Biliary Tract Cancer; FDA Clears Boehringer\u2019s Spesolimab; Novo Nordisk to Acquire Forma Therapeutics; Sanofi\u2019s Xenpozyme Approved for ASMD; Another FDA Approval to Azurity\u2019s Konvomep; Amgen\u2019s Lumakras Trial Results; FDA Grants Priority Review to Sanofi &#038; Sobi\u2019s efanesoctocog alfa; Neurocrine Bio to Takeover UK Biotech Diurnal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f094eadbba8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f094eadbba8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#FDA_Approves_AstraZenecas_Imfinzi_for_Biliary_Tract_Cancer\" >FDA Approves AstraZeneca\u2019s Imfinzi for Biliary Tract Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#FDA_Clears_Boehringer_Ingelheims_Spesolimab_for_Generalized_Pustular_Psoriasis\" >FDA Clears Boehringer Ingelheim\u2019s Spesolimab for Generalized Pustular Psoriasis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#Azurity_Pharmaceuticals_Konvomep_Wins_Another_FDA_Approval\" >Azurity Pharmaceuticals\u2019 Konvomep Wins Another FDA Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#Amgens_Lumakras_Shows_Promising_Results_in_KRAS-mutated_Non-small_Cell_Lung_Cancer_NSCLC_in_a_Phase_III_Trial\" >Amgen\u2019s Lumakras Shows Promising Results in KRAS-mutated Non-small Cell Lung Cancer (NSCLC) in a Phase III Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#Novo_Nordisk_to_Acquire_Forma_Therapeutics_for_USD_11_Billion\" >Novo Nordisk to Acquire Forma Therapeutics for USD 1.1 Billion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#Sanofis_Xenpozyme_Becomes_First_FDA-Approved_Drug_ASMD\" >Sanofi\u2019s Xenpozyme Becomes First FDA-Approved Drug ASMD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#FDA_Sets_New_Priority_Review_Date_of_Sanofi_and_Sobis_Hemophilia_A_Drug_Efanesoctocog_Alfa\" >FDA Sets New Priority Review Date of Sanofi and Sobi\u2019s Hemophilia A Drug Efanesoctocog Alfa&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\/#Neurocrine_Bio_Agrees_USD_57_Million_Takeover_of_UK_Biotech_Diurnal\" >Neurocrine Bio Agrees USD 57 Million Takeover of UK Biotech Diurnal<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-astrazeneca-s-imfinzi-for-biliary-tract-cancer\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AstraZenecas_Imfinzi_for_Biliary_Tract_Cancer\"><\/span><strong>FDA Approves AstraZeneca\u2019s Imfinzi for Biliary Tract Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Imfinzi<\/strong>, a checkpoint inhibitor developed by <strong>AstraZeneca<\/strong>, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. <strong>Imfinzi (durvalumab)<\/strong> has been approved by the Food and Drug Administration for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\">treatment of locally advanced or metastatic biliary tract cancer<\/a> in adults in combination with gemcitabine\/cisplatin chemotherapy, extending Imfinzi\u2019s use beyond lung cancer for the first time.<\/p>\n\n\n\n<p>The approval follows the <strong>TOPAZ-1 trial<\/strong>, which demonstrated that adding Imfinzi to standard first-line chemotherapy for BTC increased overall survival compared to chemo alone without significantly increasing the side-effect burden. In the trial, roughly <strong>25%<\/strong> of patients who received Imfinzi\/chemo were still alive two years later, compared to <strong>10%<\/strong> of patients in the chemo-plus placebo group.<\/p>\n\n\n\n<p>Biliary tract cancer affects the bile ducts and gallbladder, with approximately <strong>23,000<\/strong> cases diagnosed annually in the United States. Life expectancy is low, with only <strong>5% to 15%<\/strong> of patients expected to live past the age of 5. Because the disease can be asymptomatic in the early stages, patients frequently progress to the more severe disease before receiving treatment, when options are limited, and the prognosis is poor.<\/p>\n\n\n\n<p>According to <strong>TOPAZ-1<\/strong> lead investigator <strong>Aiwu Ruth He of Medstar Georgetown University Hospital<\/strong> in Washington DC, the improvement in survival seen with Imfinzi is significant, as this has not been seen for a new BTC therapy in many years. <strong>Imfinzi\u2019s <\/strong>FDA-approved indications in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\">NSCLC<\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/small-cell-lung-cancer-market\">SCLC<\/a> helped drive sales of the PD-L1 inhibitor to <strong>USD 1.3 billion<\/strong> in the first half of this year. It has also been filed for BTC in the United Kingdom, Australia, Brazil, Canada, Israel, and Singapore, with an EU filing expected soon.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Clears_Boehringer_Ingelheims_Spesolimab_for_Generalized_Pustular_Psoriasis\"><\/span><strong>FDA Clears Boehringer Ingelheim\u2019s Spesolimab for Generalized Pustular Psoriasis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Boehringer Ingelheim<\/strong> has received the first regulatory approval in the United States for <strong>spesolimab<\/strong>, an antibody therapy for the rare and life-threatening skin disorder generalized pustular psoriasis (GPP). The FDA has approved the IL-36 receptor inhibitor Spevigo to treat the devastating flares of painful blisters that are a feature of GPP. The flares can be severe enough to require patients to be hospitalized with complications such as heart failure, renal failure, and sepsis. The mortality rate after GPP flares ranges from <strong>2% to 16%<\/strong>, with septic shock and cardiorespiratory failure being the leading causes of death.&nbsp;<\/p>\n\n\n\n<p><strong>Spevigo <\/strong>is the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-pustular-psoriasis-market\">GPP therapy<\/a> to be approved and the first IL-36 inhibitor to make it through development and onto the market. European regulators are also reviewing it, with a decision expected before the end of the year. The approval follows the recently published <strong>EFFISAYIL 1 trial<\/strong>, in which a single intravenous dose of spesolimab was compared to a placebo in <strong>53<\/strong> people with a GPP flare characterized by a high or very high density of pustules on the skin.<\/p>\n\n\n\n<p>Around <strong>54%<\/strong> of patients treated with spesolimab had no visible pustules on their skin a week after dosing, compared to <strong>6%<\/strong> of those treated with placebo. According to the data, the protective effect lasted up to 12 weeks.<\/p>\n\n\n\n<p>Other drugs that inhibit other cytokines, such as<strong> TNF, IL-17, and IL-23 inhibitors<\/strong>, are currently used off-label to help patients experiencing a flare, but there is limited evidence for their efficacy. The <strong>EFFISAYIL 1 trial<\/strong> was led by <strong>Mark Lebwohl of the Icahn School of Medicine<\/strong> at Mount Sinai in New York, United States, who described the approval as a \u201cturning point\u201d for patients with GPP and their clinicians.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Azurity_Pharmaceuticals_Konvomep_Wins_Another_FDA_Approval\"><\/span><strong>Azurity Pharmaceuticals\u2019 Konvomep Wins Another FDA Approval<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Azurity Pharmaceuticals<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> had approved <strong>Konvomep (omeprazole and sodium bicarbonate for oral suspension)<\/strong>. Konvomep is approved for treating active <strong>benign gastric ulcers<\/strong> and reducing the risk of bleeding in <strong>upper gastrointestinal portion<\/strong> in critically ill patients.<\/p>\n\n\n\n<p>&#8220;We are glad that patients will soon have access to this <strong>FDA-approved oral liquid formulation<\/strong> option of a commonly prescribed <strong>proton pump inhibitor<\/strong>,&#8221; said Richard Blackburn, CEO, Azurity Pharmaceuticals. &#8220;Patients are our priority, and our aim is to bring them new formulations that help them benefit from established medicines. Konvomep may offer patients, particularly patients having difficulty swallowing pills or capsules, an option for treatment tailored to their needs.&#8221;<\/p>\n\n\n\n<p>&#8220;Patients who struggle with taking solid oral dosage forms may be overlooked and have historically had limited FDA-approved treatment options available as liquid formulations,&#8221; said Olga Hilas, Professor, Clinical Health Professions, St. John&#8217;s University College of Pharmacy &amp; Health Sciences, Queens, New York.<\/p>\n\n\n\n<p>It is expected that <strong>Konvomep <\/strong>will become commercially available in pharmacies nationwide in first quarter of 2023.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amgens_Lumakras_Shows_Promising_Results_in_KRAS-mutated_Non-small_Cell_Lung_Cancer_NSCLC_in_a_Phase_III_Trial\"><\/span><strong>Amgen\u2019s Lumakras Shows Promising Results in KRAS-mutated Non-small Cell Lung Cancer (NSCLC) in a Phase III Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Amgen <\/strong>announced that the <strong>global Phase III CodeBreaK 200 trial<\/strong> accessing <strong>once-daily oral LUMAKRAS (sotorasib)<\/strong> met its primary end-point of <strong>progression-free survival<\/strong>, illustrating statistical significance and superiority over the <strong>standard of care chemotherapy, intravenous docetaxel<\/strong>. The first randomized clinical trial for a <strong>KRASG12C inhibitor<\/strong> evaluated the efficiency and safety of <strong>LUMAKRAS <\/strong>in approximately <strong>340 previously treated patients<\/strong> suffering with <strong>KRAS G12C-mutated <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>non-small cell lung cancer<\/strong><\/a> who received at minimum prior <strong>platinum-based doublet chemotherapy<\/strong> and <strong>checkpoint-inhibitor therapy<\/strong>.<\/p>\n\n\n\n<p>Amgen took on one of the difficult challenges of the last <strong>40 years<\/strong> in cancer research by developing <strong>LUMAKRAS\/LUMYKRAS<\/strong>, a <strong>KRASG12C inhibitor<\/strong>. LUMAKRAS\/LUMYKRAS has demonstrated a favourable benefit-risk profile with rapid, profound, and durable anti-cancer activity in patients suffering with locally <strong>advanced or metastatic non-small cell lung cancer<\/strong> harboring the <strong>KRAS G12C mutation<\/strong> with a once-daily oral formulation.<\/p>\n\n\n\n<p>Amgen is progressing the most extensive and broadest global <strong>KRASG12C inhibitor development program<\/strong> with unparalleled speed and exploring more than <strong>ten sotorasib combination regimens<\/strong>, including triplets, with clinical trial sites spanning 5 continents. Upto date, around <strong>6,500 patients<\/strong> around the world have received LUMAKRAS\/LUMYKRAS through the clinical development program, expanded access and commercial use.\u00a0LUMAKRAS\/LUMYKRAS is Being Studied in Various Other Solid Tumors<\/p>\n\n\n\n<p><strong>Lung cancer<\/strong> is the main cause of <strong>cancer-related deaths<\/strong> globally, and accounts for more deaths worldwide than <a href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-market-insights\"><strong>breast cancer<\/strong><\/a><strong>, <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\"><strong>prostate cancer<\/strong><\/a>, and <strong>colon cancer<\/strong> combined. Overall survival rates for <strong>non-small cell lung cancer<\/strong> are improving but remain poor for patients suffering with advanced disease, and <strong>5-year survival rate<\/strong> is only <strong>8 per cent<\/strong> for those with <strong>metastatic disease<\/strong>.<\/p>\n\n\n\n<p>The <strong>CodeBreaK clinical development program<\/strong> for <strong>Amgen&#8217;s <\/strong>drug <strong>sotorasib <\/strong>is directed to study patients with an advanced solid tumour with the <strong>KRAS G12C mutation<\/strong> and address the longstanding unmet medical need for these cancers.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_to_Acquire_Forma_Therapeutics_for_USD_11_Billion\"><\/span><strong>Novo Nordisk to Acquire Forma Therapeutics for USD 1.1 Billion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In one of the major acquisition updates in the healthcare industry, Novo Nordisk has announced that it has signed an agreement to acquire <strong>Forma Therapeutic<\/strong>. As per the definitive agreement, Novo Nordisk will acquire Forma Therapeutics for <strong>$20 per share<\/strong> in cash, which represents a total equity value of<strong> $1.1 billion<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Additionally, Novo Nordisk will also take control of the Forma Therapeutics lead development candidate, <strong>etavopivat<\/strong>. Etavopivat is an investigational, once-daily, selective pyruvate kinase-R (PKR) activator designed to be a disease-modifying therapy with the potential to improve red blood cell health and <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-pipeline-insight\"><strong>transform sickle cell disease treatment<\/strong><\/a><strong> <\/strong>scenarios. Novo Nordisk, over the past 40 years, has been actively working to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. The accession of Etavopivat will greatly complement and accelerate Novo Nordisk\u2019s strategy to grow its scientific presence and pipeline in hemoglobinopathies, a group of disorders in which there is abnormal production or structure of the hemoglobin protein in the red blood cells.<\/p>\n\n\n\n<p>Forma Therapeutics is a clinical-stage biopharmaceutical company actively engaged in the research, development and commercialization of novel therapeutics for the treatment of rare hematologic diseases and cancers, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-epidemiology-forecast\"><strong>sickle cell disease (SCD)<\/strong><\/a>. Forma Therapeutics has outstanding clinical development capabilities and generated a broad proprietary portfolio in the hematologic drug development segment based on differentiated mechanisms of action. The acquisition of Forma Therapeutics is expected to enhance Novo Nordisk\u2019s market position in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-market\"><strong>sickle cell disease therapeutics market<\/strong><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sanofis_Xenpozyme_Becomes_First_FDA-Approved_Drug_ASMD\"><\/span><strong>Sanofi\u2019s Xenpozyme Becomes First FDA-Approved Drug ASMD<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the drug regulatory updates segment, the US FDA has approved Sanofi\u2019s XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of <a href=\"https:\/\/www.delveinsight.com\/report-store\/acid-sphingomyelinase-deficiency-asmd-market\"><strong>Acid Sphingomyelinase Deficiency (ASMD)<\/strong><\/a>, often referred to as Niemann-Pick disease, in adult and pediatric patients. With the FDA\u2019s approval, Xenpozyme is the first therapy approved specifically for treating ASMD and is currently the only approved treatment for this disease.<\/p>\n\n\n\n<p>The approval of Xenpozyme is based on the positive outcome from the ASCEND and ASCEND-Peds clinical trials. In the ASCEND and ASCEND-Peds clinical trials, Xenpozyme demonstrated clinically suitable improvement in lung function, platelet count, and reduction of spleen and liver volumes, with a demonstrated safety profile. Xenpozyme is approved only for ASMD symptoms unrelated to the central nervous system.<\/p>\n\n\n\n<p>ASMD is an extremely rare, progressive genetic disease that results from a deficiency of the enzyme acid sphingomyelinase and it leads to a significant morbidity and mortality. As per the estimates, fewer than 120 patients are diagnosed with ASMD in the US, and nearly two-thirds of <a href=\"https:\/\/www.delveinsight.com\/report-store\/acid-sphingomyelinase-deficiency-asmd-epidemiology-forecast\"><strong>patients with ASMD<\/strong><\/a> are children. Moreover, some of them survive only until two or three years of age. As of now, the management of ASMD includes supportive care to address the impact of individual symptoms. However, the launch of the Xenpozyme is expected to improve the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acid-sphingomyelinase-deficiency-asmd-pipeline-insight\"><strong>ASMD treatment<\/strong><\/a> scenario in the coming years immensely.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Sets_New_Priority_Review_Date_of_Sanofi_and_Sobis_Hemophilia_A_Drug_Efanesoctocog_Alfa\"><\/span><strong>FDA Sets New Priority Review Date of Sanofi and Sobi\u2019s Hemophilia A Drug Efanesoctocog Alfa&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>US FDA recently gave Sanofi and Sobi a green flag for the approval of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a2030-market\">hemophilia A drug<\/a> candidate efanesoctocog alfa. The approval is due in the initial of 2023. Efanesoctocog alfa is a long-lasting hemophilia A that promises to deliver close to normal <strong>Factor VIII<\/strong> activity levels, potentially offering a promising relief for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a-pipeline-insight-2020\">haemophilia A patients.<\/a> Such tremendous therapeutic candidates demonstrate the advances in the medical segment and offer reliable cures, which may later transform the <strong>polylactic treatment landscape.&nbsp;<\/strong><\/p>\n\n\n\n<p>Sobi and Sanofi, which occupy a considerable market size, are now planning to deliver an application seeking the approval of the hemophilia A drug candidate efanesoctocog alfa in Europe in 2023. The application will soon be applied once the outcomes from the <strong>phase III<\/strong> <strong>XTEND-Kids study (NCT04759131)<\/strong> can be seen. The drug was evaluated in <strong>159 patients,<\/strong> mainly adults and adolescents <strong>12 years<\/strong> or older. Phase III focuses on <a href=\"https:\/\/www.delveinsight.com\/report-store\/acquired-hemophilia-a-market\">trials on young children with severe hemophilia A<\/a> which occupy most of the diseased population. Previously efanesoctocog alfa was granted the Orphan drug designation<strong> by Europe, and the FDA earned <\/strong>efanesoctocog alfa the designation of <strong>breakthrough therapy, orphan drug and fast track.&nbsp;<\/strong><\/p>\n\n\n\n<p>During the study, the results suggested that efanesoctocog alfa gradually reduced annual bleeding rates upto <strong>77% <\/strong>compared to the preexisting therapies. Additionally, the drug entity showed reduced pain and improved joints.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neurocrine_Bio_Agrees_USD_57_Million_Takeover_of_UK_Biotech_Diurnal\"><\/span><strong>Neurocrine Bio Agrees USD 57 Million Takeover of UK Biotech Diurnal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Neurocrine Biosciences, known for potential capturing key players, has now decided to acquire UK Biotech Diurnal. The deal will ultimately increase the company&#8217;s potential for making therapeutic candidates for hormonal disorders. The deal was closed at a whopping <strong>57 million.<\/strong> <strong>Diurnal, founded in 2004,<\/strong> is a key pharma player that majorly focuses on therapies for rare and chronic endocrine conditions. The potential drug candidates include those to <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypothyroidism-market\">cure hypothyroidism<\/a>,<a href=\"https:\/\/www.delveinsight.com\/report-store\/hypogonadism-market\"> hypogonadism, and other<\/a> endocrine complexities.&nbsp;<\/p>\n\n\n\n<p>The deal will probably be finalised in the last week of October or the initial week of November. Neurocrine Biosciences is a major key player that occupies a considerable market <a href=\"https:\/\/www.delveinsight.com\/report-store\/tardive-dyskinesia-market\">size in tardive dyskinesia<\/a>, Parkinson\u2019s disease, endometriosis, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/uterine-fibroids-market\">uterine fibroids segment.&nbsp;<\/a><\/p>\n\n\n\n<p>The pence per share of Duinal is also seen to <strong>boost upto 134%, accounting for 26.35 pence per share. <\/strong>The rise was seen soon after the company announced its with Neurocrine Biosciences. The shareholders of Durinal are expected to<strong> receive 27.5 pence per share<\/strong> as per the closing price on<strong> August 26. <\/strong>However, the deal is subject to terms and conditions per Durinal shareholders.&nbsp; The ultimate price per share was doubled after the deal closed.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves AstraZeneca\u2019s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by the Food and Drug Administration for the treatment [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":18774,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19706,19197,16752,19705,4932,19707,349,365,420,979,1111,639,5587,5789,15574,536],"industry":[17225],"therapeutic_areas":[17237,17239,17233,17227,17228,17234],"class_list":["post-18772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acid-sphingomyelinase-deficiency-asmd","tag-asmd","tag-biliary-tract-cancer","tag-gastric-ulcers","tag-generalized-pustular-psoriasis","tag-haemophilia-a","tag-latest-pharma-news","tag-lung-cancer","tag-news","tag-non-small-cell-lung-cancer-nsclc","tag-nsclc","tag-pharma-news","tag-psoriasis","tag-recent-pharma-news","tag-sclc","tag-sickle-cell-disease","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-gastroenterology","therapeutic_areas-hematological-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Azurity, Sobi, Sanofi, Amgen, AstraZeneca, Novo Nordisk<\/title>\n<meta name=\"description\" content=\"AstraZeneca\u2019s Imfinzi; Boehringer\u2019s Spesolimab; Sanofi\u2019s Xenpozyme; Azurity\u2019s Konvomep; Amgen\u2019s Lumakras; Sanofi &amp; Sobi\u2019s efanesoctocog alfa\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Azurity, Sobi, Sanofi, Amgen, AstraZeneca, Novo Nordisk\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca\u2019s Imfinzi; Boehringer\u2019s Spesolimab; Sanofi\u2019s Xenpozyme; Azurity\u2019s Konvomep; Amgen\u2019s Lumakras; Sanofi &amp; Sobi\u2019s efanesoctocog alfa\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T12:08:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-06T15:08:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Azurity, Sobi, Sanofi, Amgen, AstraZeneca, Novo Nordisk","description":"AstraZeneca\u2019s Imfinzi; Boehringer\u2019s Spesolimab; Sanofi\u2019s Xenpozyme; Azurity\u2019s Konvomep; Amgen\u2019s Lumakras; Sanofi & Sobi\u2019s efanesoctocog alfa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Azurity, Sobi, Sanofi, Amgen, AstraZeneca, Novo Nordisk","og_description":"AstraZeneca\u2019s Imfinzi; Boehringer\u2019s Spesolimab; Sanofi\u2019s Xenpozyme; Azurity\u2019s Konvomep; Amgen\u2019s Lumakras; Sanofi & Sobi\u2019s efanesoctocog alfa","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-09-06T12:08:27+00:00","article_modified_time":"2022-09-06T15:08:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen","name":"Pharma News | Azurity, Sobi, Sanofi, Amgen, AstraZeneca, Novo Nordisk","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi.png","datePublished":"2022-09-06T12:08:27+00:00","dateModified":"2022-09-06T15:08:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"AstraZeneca\u2019s Imfinzi; Boehringer\u2019s Spesolimab; Sanofi\u2019s Xenpozyme; Azurity\u2019s Konvomep; Amgen\u2019s Lumakras; Sanofi & Sobi\u2019s efanesoctocog alfa","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-azurity-sobi-sanofi-amgen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi.png","width":772,"height":482,"caption":"Pharma News for Azurity, Sobi, and Sanofi"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/06173343\/Pharma-News-for-Azurity-Sobi-and-Sanofi-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acid Sphingomyelinase Deficiency (ASMD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ASMD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biliary tract cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gastric ulcers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Generalized pustular psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">haemophilia A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">sickle cell disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acid Sphingomyelinase Deficiency (ASMD)<\/span>","<span class=\"advgb-post-tax-term\">ASMD<\/span>","<span class=\"advgb-post-tax-term\">Biliary tract cancer<\/span>","<span class=\"advgb-post-tax-term\">gastric ulcers<\/span>","<span class=\"advgb-post-tax-term\">Generalized pustular psoriasis<\/span>","<span class=\"advgb-post-tax-term\">haemophilia A<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">SCLC<\/span>","<span class=\"advgb-post-tax-term\">sickle cell disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Sep 6, 2022","modified":"Updated on Sep 6, 2022"},"absolute_dates_time":{"created":"Posted on Sep 6, 2022 5:38 pm","modified":"Updated on Sep 6, 2022 8:38 pm"},"featured_img_caption":"Pharma News for Azurity, Sobi, and Sanofi","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18772"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18774"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18772"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18772"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}